Results

Avita Therapeutics Inc.

12/09/2021 | Press release | Distributed by Public on 12/09/2021 05:04

Material Event - Form 8-K

8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 8, 2021

Avita Medical, Inc.

(Exact name of registrant as specified in its charter)

Delaware 001-39059 85-1021707

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

28159 Avenue Stanford, Suite 220, Valencia, CA91355 661.367.9170
(Address of principal executive offices, including Zip Code) (Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-Kfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12under the Exchange Act (17 CFR 240.14a-12)

Pre-commencementcommunications pursuant to Rule 14d-2(b)under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencementcommunications pursuant to Rule 13e-4(c)under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share RCEL The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2of the Securities Exchange Act of 1934. Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01.

Other Events.

As a point of clarification, during the fiscal year ending June 30, 2021, the Board of Directors of AVITA Medical, Inc. (the "Company") met a total of nine times. Each Director attended at least 75% of the Board meetings.

Additionally, the Committees of the Board of Directors of the Company met a total of 15 times. Each Director attended 100% of the meetings of the committees of which they were a member.

The Audit Committee met 4 times (August 25, 2020; November 9, 2020; February 10, 2021; and April 9, 2021). Each member of the Audit Committee attended 100% of the Audit Committee meetings.

The Compensation Committee met 5 times (August 7, 2020; October 8, 2020; November 5, 2020; February 9, 2021; and May 6, 2021). Each member of the Compensation Committee attended 100% of the Compensation Committee meetings.

The Nominations and Corporate Governance Committee met 6 times (August 7, 2020; October 8, 2020; November 5, 2020; February 9, 2021; April 13, 2021; and May 6, 2021). Each member of the Nominations and Corporate Governance Committee attended 100% of the Nominations and Corporate Governance Committee meetings.

The information under this Item 8.01 is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be deemed incorporated by reference into any filing made under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 8, 2021

AVITA MEDICAL, INC.
By:

/s/ Donna Shiroma

Name: Donna Shiroma
Title: General Counsel